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Background: Ten years after the first proposal, a consensus definition of healthcare-associated infection (HCAI) has
not been reached, preventing the development of specific treatment recommendations. A systematic review of all
definitions of HCAI used in clinical studies is made.
Methods: The search strategy focused on an HCAI definition. MEDLINE, SCOPUS and ISI Web of Knowledge were
searched for articles published from earliest achievable data until November 2012. Abstracts from scientific
meetings were searched for relevant abstracts along with a manual search of references from reports, earlier
reviews and retrieved studies.
Results: The search retrieved 49,405 references: 15,311 were duplicates and 33,828 were excluded based on title
and abstract. Of the remaining 266, 43 met the inclusion criteria. The definition more frequently used was the initial
proposed in 2002 - an infection present at hospital admission or within 48 hours of admission in patients that
fulfilled any of the following criteria: received intravenous therapy at home, wound care or specialized nursing care
in the previous 30 days; attended a hospital or hemodialysis clinic or received intravenous chemotherapy in the
previous 30 days; were hospitalized in an acute care hospital for ≥2 days in the previous 90 days, resided in a
nursing home or long-term care facility. Additional criteria founded in other studies were: immunosuppression,
active or metastatic cancer, previous radiation therapy, transfer from another care facility, elderly or physically
disabled persons who need healthcare, previous submission to invasive procedures, surgery performed in the last
180 days, family member with a multi-drug resistant microorganism and recent treatment with antibiotics.
Conclusions: Based on the evidence gathered we conclude that the definition initially proposed is widely
accepted. In a future revision, recent invasive procedures, hospitalization in the last year or previous antibiotic
treatment should be considered for inclusion in the definition. The role of immunosuppression in the definition of
HCAI still requires ongoing discussion.
Keywords: Healthcare-associated infection, Classification, Multidrug resistant pathogens prevalence, Pneumonia,
Bloodstream infections, Endocarditis, Urinary tract infections, Intra-abdominal infectionsBackground
Traditionally, infections have been classified as commu-
nity or hospital-acquired, according to their place of ac-
quisition, and this classification is still used to guide
treatment decisions [1,2].
Over the last decade the massive increase in outpatient
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unless otherwise stated.of healthcare-associated infections (HCAI). This is a new
name for a new group of infections emerging among pa-
tients that come from the community with a history of pre-
vious exposure to healthcare who do not fit the nosocomial
infection criteria. The proportion of patients hospitalized
with HCAI among those admitted from the community
setting can be as high as 50% [3-6].
The first proposals of HCAI and its inclusion in infection
classification along with community-acquired infection
(CAI) and hospital-acquired infection (HAI) were made
in 2002 by Siegman-Igra et al. [7] and Friedman et al.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Friedman et al. [3] has been used in numerous clinical
studies and will be referred to in this review as the ini-
tial definition; it is defined as an infection present at
hospital admission or within 48 hours of admission in
patients that fulfilled any of the following criteria:
– received intravenous therapy at home, wound care
or specialized nursing care through a healthcare
agency, family or friends; or had self-administered
intravenous medical therapy in the 30 days before
the infection;
– attended a hospital or hemodialysis clinic or
received intravenous chemotherapy in the previous
30 days;
– were hospitalized in an acute care hospital for 2 or
more days in the previous 90 days,
– resided in a nursing home or long-term care facility.
Although widely accepted [5,8-10] numerous alternative
definitions have also been used in clinical studies [11-14].
This heterogeneity has raised more confusion than under-
standing in determining likely microbiological resistance
patterns and making decisions about empiric antibiotic
treatment. A correct recognition of all risk factors for
HCAI is crucial in guaranteeing optimal empiric antibiotic
choice to adequately treat likely pathogens while avoiding
selective pressure that contributes to the development of
multidrug-resistant (MDR) organisms.
The objective of the current study is to present a system-
atic review of all definitions of HCAI used in clinical studies
in order to compare and contrast the criteria they include.
Methods
Data sources and searches
This search was performed in accordance with the
recommendations of the Cochrane collaboration using
MEDLINE/PubMed, SCOPUS and ISI Web of Knowledge
from the earliest achievable data until November 2012. A
manual search of references from reports, earlier reviews
and retrieved studies was also performed. Abstract books
and CD-ROMs from several annual scientific meetings
were searched for relevant abstracts (Figure 1). No language
restriction was applied and papers written in a foreign
language were translated.
The electronic search strategy covered the main subject
area: healthcare-associated infection (Additional file 1:
Search strategy details). The last search was done on 8
November 2012.
Study selection
The inclusion criteria were all observational studies
(cohort, cross-sectional or case–control) on adult patients
admitted to hospital that provided microbiology resultsaccording to place of acquisition of infection. The following
definitions of infection by setting were used:
– CAI - infection detected within 48 hours of hospital
admission in patients without previous contact with
healthcare service.
– HAI - localized or systemic condition: 1) that results
from adverse reaction to the presence of an infectious
agent(s) or its toxin(s) and 2) that was present
48 hours or more after hospital admission and not
incubating at hospital admission time [15].
– HCAI - infection detected within 48 hours of hospital
admission in patients that had previous contact with
healthcare service within one year.
Data extraction and quality assessment
The results of the literature search were accessed by two
reviewers (TC, MA) and non-relevant studies were
excluded based on title and abstract. For potentially
relevant studies, the full text was obtained, and two in-
vestigators (TC, MA) independently assessed study eli-
gibility and extracted data on study design, objectives,
HCAI definitions and multi-drug resistant pathogens
(MDR) prevalence (Methicillin-resistant Staphylococcus
aureus (MRSA), Pseudomonas aeruginosa, Acinectobacter,
Stenotrophomas maltophilia, extended-spectrum beta
lactamases producer (ESBL)), using a data extraction
protocol; disagreements were resolved through consultation
with a third reviewer (LA).
Each selected study was independently evaluated by two
reviewers (TC, MA) for the strength of evidence through
examination of the study design and quality of data.
Potential threats to the internal validity of included stud-
ies were evaluated considering the following criteria:
– The authors define inclusion criteria,
– The authors define an adequate selection method,
– The selection of participants was consecutive,
– The outcome data (microbiology data by place of
acquisition) were complete and reported
(no attrition bias) and
– All results were reported (reporting bias).
Studies that met all of the above five criteria, were
classified as “low risk of bias”. Studies that partially met
one or more criteria were classified as “moderate risk of
bias”. Studies were classified as “high risk of bias” if one or
more of these criteria was not met.
Data analysis
Data on individual studies included are provided in Tables 1
and 2. A meta-analysis was not performed due to the
nature of the objectives of this review and the hetero-
geneity of the studies included.
Figure 1 Flow diagram of study selection.
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The search retrieved a total of 49,405 references. Of the
266 studies included in the first review, 106 were review
articles or opinion pieces and 117 did not meet inclusion
criteria. Of the remaining 52 studies: 30 used the initial
definition of Friedman et al. [3], but only 21 provided
data on microbiology and were included along with 22
additional studies that used alternative definitions and
met the inclusion criteria. Of the 43 studies included in
this systematic review (Figure 1): 18 were prospective
(7 multicenter and 11 single center) and 25 were retro-
spective (9 multicenter and 16 single center); involving
42,611 patients.
Characteristics of included studies that used the initial
definition are shown in Table 1 and of those that used
alternative definitions in Table 2.
Infections by source
In bloodstream HCAIs, six studies used the initial def-
inition [3] (Table 1) and six did not (Table 2), all found
an increasing prevalence of MDR organisms from CAI
to HCAI and HAI, regardless of the definition used.
The majority of the included studies were about
pneumonia (24 studies of 43). Most of these studiesonly compared community-acquired pneumonia (CAP)
with healthcare-associated pneumonia (HCAP) and re-
vealed a higher prevalence of MDR pathogens among
HCAP patients compared with CAP patients. There were
three studies comparing CAP and HCAP with hospital
acquired pneumonia (HAP) [13,21,42] but they used
different definitions of HCAP achieving different results
regarding MDR prevalence according to place of acquisi-
tion of infection (Tables 1 and 2).
There were three studies of healthcare-associated infect-
ive endocarditis [5,29,46]. Two found an increasing rate of
MDR organisms from community-acquired to healthcare-
associated and hospital-acquired infective endocarditis
(Table 1). A third study compared healthcare-associated
infective endocarditis with non-healthcare-associated
infective endocarditis (that is, community-acquired plus
hospital-acquired infective endocarditis) and found a higher
prevalence of MDR in healthcare-associated infective
endocarditis than in non-healthcare-associated infective
endocarditis (Table 2).
Studies regarding urinary tract [6,45] and intra-abdominal
[43] infections also found a higher prevalence of MDR
organisms, among HCAIs when compared to CAIs
(Tables 1 and 2).
Table 1 Characterization of included studies that use the initial definition of HCAI [3] by focus of infection
Author, publication year Study design MDR* organisms, n (%) Risk of bias
Bacteriemia CAI HCAI HAI
Friedman et al., 2002 [3] Prospective, multicenter, 504 patients, USA, 4 to 5 months Not mentioned High
Marschall et al., 2009 [16] Prospective, single center, 250 patients, Gram-negative, USA, 6 months 0 (0) 9 (7) 10 (11) Low
Evans et al., 2009 [17] Retrospective, multicenter, 223 patients, spinal cord injury, USA, 7 years 6 (17) 34 (31) 111 (42) High
Son et al., 2010 [18] Prospective, multicenter, 1,144 patients, Korea, 12 months 29 (8) 38 (7) 162 (79) Low
Rodriguez-Bano et al.,
2010 [19]
Prospective, multicenter, 821 bacteremia episodes including potential
contaminants, Spain, 2 to 5 months
7 (5) 29 (15) 99 (21) Moderate
Vallés et al., 2011 [8] Prospective, multicenter, 726 patients, Spain and Argentina, 12 months 7 (2) 11 (8) 29 (12) High
Pneumonia CAI HCAI
Carratalà et al., 2007 [10] Prospective, single center, 727 patients, those with neutropenia, AIDS
and after transplantation were excluded, Spain, 4 years.
3 (1) 2 (2) Low
Shindo et al., 2009 [20] Retrospective, single center, 371 patients, Japan, 1 year and 3 months 6 (6) 17 (22) Low
Park et al., 2010 [9] Retrospective, single center, 345 patients, CAI and HCAI were considered
until 72 h after hospital admission; patients with neutropenia, AIDS and
after transplantation were excluded, Korea, 1 year.
7 (15) 21 (32) Moderate
Pascual et al., 2010 [21] Retrospective, single center, 308 patients with bacteriemic pneumonia,
Spain, 6 years
CAI (2) HCAI (12) HAI (31) High
Umeki et al., 2011 [22] Prospective, single center, 202 patients, Japan, 2 years 10 (21) 12 (25) Moderate
Seki et al., 2011 [23] Retrospective, single center, 34 patients Japan, 4 months 0 (0) 6 (43) Moderate
Garcia-Vidal et al., 2011 [24] Prospective, single center, 2,153 patients, those with more than one
condition of HCAI, with neutropenia, AIDS, after transplantation and chronic
corticosteroid treatment were excluded, Spain, 8 years and 9 months
19 (2) 7 (2) Low
Jung et al., 2011 [25] Retrospective, single center, 527 patients, Korea, 1 year 15 (18) 30 (38) Low
Jeon et al., 2011 [26] Retrospective, multicenter, 210 patients older than 60 years, Korea,
2 years.
10 (16) 20 (67) Low
Depuydt et al. 2011 [27] Retrospective, single center, 269 patients, those with neutropenia,
transplantation or transferred from another hospital were excluded,
Belgium, 1 year
0 (0) 6 (30) Low
Park et al., 2012 [4] Prospective, single center, 339 patients, Korea, 2 years 35 (20) 52 (31) Low
Lee et al., 2012 [28] Retrospective, multicenter study, 250 patients, Korea, 21 months 3 (4) 17 (31) Low
Other foci CAI HCAI HAI
Benito et al., 2009 [5] Prospective, single center,1622 patients with endocarditis, comparing
CAI with healthcare associated that included non-nosocomial and
nosocomial, intra-venous drug users and prosthetic valves were
excluded, USA, 6 months.
25 (3) 41 (17) 76 (26) Low
Wu et al., 2011 [29] Retrospective, single center,192 patients with endocarditis, Taiwan, 5 years 15 (11) 13 (43) 17 (81) Moderate
Aguilar-Duran et al., 2012 [6] Prospective, single center, 251 patients with urinary infection, Spain,
7 to 8 months
2 (2) 15 (15) 9 (14) High
*MDR, MRSA, Pseudomonas sp, Acinectobacter, Stenotrophomonas maltophilia, ESBL. CAI, community-acquired infection; HAI, hospital-acquired infection; HCAI,
healthcare-associated infection; MDR, multidrug-resistant.
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clinical studies (30 studies among 52). Overall, different
HCAI definitions comprised 17 different criteria, of which
7 were equivalent to those used by Friedman et al. [3], but
leading to a different final definition due to the addition
or subtraction of criteria (Table 3).
An analysis of the risk of bias of the 43 included studies
revealed that 24 presented a low risk of bias, 7 presented a
moderate risk of bias, and 12 presented a high risk of bias,
according to previously defined criteria (Additional file 2:eTable 1 - Studies with moderate or high risk of bias
according to pre-defined criteria).
Discussion
Ten years after the first descriptions [3,7], this is the
first systematic review of HCAI classification. It incor-
porates all published studies on HCAI that provided
original data. The majority of the included studies had
a low risk of bias, resulting in good quality of the evi-
dence assembled.
Table 2 Characterization of included studies that did not use the initial definition of HCAI [3] by focus of infection
Study, year
of publication
Study design HCAI criteria MDR* organisms Risk of bias
A. Bloodstream infections
Siegman-Igra et al.,
2002 [7]
Prospective, single center, 1,028
infections in 912 patients; Israel, 1 year
1. Discharge from hospital 2 to 30 days
previously
CAI HCAI HAI Moderate
2. Nursing-home acquired 8 (2) 24 (10) 71 (17)
3. Patients with long-term intravenous
devices, for hemodialysis, chemotherapy or
parenteral nutrition
4. Chronic hemodialysis
5. Invasive procedure previously or at
hospital admission
Shorr et al.,
2006 [11]
Retrospective, multicenter, 6,697
patients; USA, 2 years
1. Prior hospitalization within 30 days CAI HCAI HAI Low
2. Transfer from another healthcare facility 152 (2) 397 (11) 62 (13)
3. Chronic hemodialysis
4. Immunosuppression medication or
metastatic cancer
Kao et al.,
2011 [30]
Prospective, single center, 890
infections in 831 patients older than
14 years; Taiwan, 1 year
1. Hospitalized for 2 or more days in the
previous 90 days
CAI HCAI HAI High
2. Resided in a nursing home 11 (2) 41 (16) 42 (41)
3. Hemodialysis, intravenous chemotherapy
or invasive procedures in the previous 90 days
Kollef et al.,
2011 [12]
Prospective, multicenter, 1,143
patients; USA, 1 year
1. Prior hospitalization within 6 months CAI HCAI Low
2. Admission from a skilled nursing facility 79 (19) 242 (33)
3. Hemodialysis
4. Immunosuppression
Al-Hasan et al.,
2012 [31]
Retrospective, multicenter, 733
episodes of gram negative bacteremia;
excludes polymicrobial, nosocomial
and recurrent episodes; USA, 10 years
1. Hospitalized for 2 or more days in the
previous 90 days
CAI HCAI Moderate
2. Residents in a nursing home or long-term
care facility
12 28 (7)
3. Received intravenous therapy including
ATB and chemotherapy
4. Hemodialysis in the previous 30 days
Lenz et al.,
2012 [32]
Retrospective, multicenter, 7,712
patients; only samples obtained in
the first 5 days of hospital admission;
Canada, 8 years
1. Hospitalized for 2 or more days in the
previous 90 days
CAI HCAI HAI Low
2. Nursing home or long term-care facility 59 (2) 158 (6) 202 (9)
3. Visit a hospital, clinic or emergency
department within the prior 5 to 30 days
4. Hemodialysis
5. Active cancer
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(Continued)
B. Pneumonia
Kollef et al.,
2006 [13]
Retrospective, multicenter,
4,543 patients with positive
cultures within 5 days of
hospital admission, USA,
2 years
1. Prior hospitalization within 30 days CAI HCAI HAI High
2. Admission from another care facility 624 (28) 537 (54) 362 (43)
3. Receiving long-term hemodialysis
Micek et al.,
2007 [33]
Retrospective, single center, 639
patients older than 16 years with
positive cultures, Spain, 2 years
1. Hospitalization in the past 12 months CAI HCAI Low
2. Resident in a nursing home or long-term
care facility or rehabilitation hospital
35 (17) 242 (56)
3. Outpatient hemodialysis, peritoneal
dialysis or infusion therapies requiring
regular visits to a clinic
4. Immunosuppression
Schreiber et al.,
2010 [34]
Retrospective, single center study,
190 patients needing mechanical
ventilation more than 24 hours after
hospital admission, patients without
evidence of bacterial infection and
patients transferred from other
hospitals were excluded, USA,
4 years
1. Recent hospitalization (90 days) CAI HCAI Low
2. Admission from a long-term facility 17 (18) 48 (48)
3. Recent treatment with broad spectrum
antibiotics (30 days)
4. Chronic hemodialysis
5. Wound care
6. Immunosuppression
Grenier et al.,
2011 [14]
Retrospective, single center study,
3,295 patients, those transferred from
other hospitals or discharged from an
acute care facility within 14 days were
excluded, Canada, 12 years
1. Hospitalization in the past 90 days, but
not in the last 14 days
CAI HCAI Low
2. Resident of a nursing home or
long-term care facility
42 (4) 21 (10)
3. Outpatient intravenous therapy or
cancer therapy within the previous month
4. Long term hemodialysis
Guimarães et al.,
2011 [35]
Retrospective, single center study,
197 patients, Portugal, 1 year
1. Hospitalization for 2 days or more in the
preceding 90 days
CAI HCAI High
2. Resident of a nursing home or
extended-care facility
2 (18) 9 (82)
3. Intravenous antibiotic therapy or
chemotherapy within 30 days
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug
resistant pathogen
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(Continued)
Chalmers et al.,
2011 [36]
Prospective, single center, 1,348
patients; Scotland, 4 years and
5 months
1. Hospitalization for 2 days or more in the
preceding 90 days
CAI HCAI High
2. Resident of a nursing home or
extended-care facility
3 (1) 5 (6)
3. Home infusion therapy (including
antibiotics and long-indwelling devices
as catheters)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug resistant
pathogen
Tasbakan et al.,
2011 [37]
Retrospective, single center study,
187 patients, Turkey, 1 year
1. Hospitalization for 2 days or more in the
preceding 90 days
CAI HCAI Low
2. Resident of a nursing home or
extended-care facility
1 (13) 17 (44)
3. Home infusion therapy
(including antibiotics)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug resistant
pathogen
Ishida et al.,
2012 [38]
Retrospective, single center, 893
patients; Japan, 3 years
1. Discharged from a hospital in the
preceding 90 days
CAI HCAI Low
2. Resident in a nursing home or
extended-care ward
6 (3) 37 (21)
3. A patient who regularly requires vascular
access for dialysis, antimicrobial treatment,
chemotherapy or immunosuppressive
therapy in an outpatient setting
4. Elderly or handicap who needs
long-term care with an ECOG of 3 or 4
Miyashita et al.,
2012 [39]
Prospective, multicenter, 1,385
patients; CAI and HCAI were
considered until 72 h after
hospital admission, Japan, 6 years
1. Discharged from a hospital in the
preceding 90 days
CAI HCAI High
2. Resident in a long-term nursing home
setting or healthcare home
21 (4) 78 (20)
3. Continuous receiving endovascular
therapy in an ambulatory setting (including
dialysis, antibiotics, anticancer drugs and
immunosuppression)
4. Elderly persons or physical disable
persons who need healthcare
Wu et al.,
2012 [40]
Retrospective, multicenter study,
1,646 patients, those with pneumonia
developing 2 days after admission or
less than 14 days after the last
hospitalization, with lung cancer
obstructive pneumonia or HIV
positive status with CD4+ t <200
were excluded, Taiwan,1 year
1. Undergoing repeated hospitalization
within 90 days before
CAI HCAI Low
2. Residing in a nursing home 122 (15) 169 (28)
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(Continued)
3. Receiving radiation therapy or
chemotherapy at an outpatient clinic
4. Received regular dialysis at an out
patients clinic
Sugisaki et al.,
2012 [41]
Retrospective, single center
study, 526 patients, Japan,
4 years
1. Hospitalization for 2 days or more in the
preceding 90 days
CAI HCAI Low
2. Resident of a nursing home or
extended-care facility
50 (15) 72 (40)
3. Home infusion therapy (including
antibiotics and long indwelling devices
as catheters)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with multi-drug
resistant pathogen
Giannella et al.,
2012 [42]
Prospective, multicenter, 1,002
patients older than 16 years
admitted into internal medicine
departments, Spain, 2 weeks
1. Hospitalization in the past 180 days CAI HCAI HAI Low
2. Resident in a nursing home or
extended-care facility
6 (4) 19 (29) 11 (52)
3. Attending a hospital regularly because
of chronic underlying disease
4. Undergoing hemodialysis
5. Wound care or specialized nursing care
in the past 30 days
6. Chemotherapy in the past 30 days
7. Surgery in the past 180 days
C. Other foci
Swenson et al.,
2009 [43]
Retrospective, single center study,
2,049 intra-abdominal infections;
Canada, 10 year
1. Patients with a story of any
hospitalization in the previous 30 days
CAI HCAI High
2. Resident of a nursing home or
rehabilitation facility in the previous 30 days
27 (7) 221 (28)
Merli et al.,
2010 [44]
Prospective, single center study,
in 54 patients with cirrhosis,
patients with HIV infection, under
high dose of corticosteroid
treatment or immunosuppressive
therapy were excluded, Italy,
9 months
1. Hospitalization for 2 or more days or
had undergone surgery during the
preceding 180 days
CAI HCAI HAI Low
2. Resident of a nursing home or
long-term care facility
2 (50) 9 (82) 5 (45)
3. Attended a hospital or hemodialysis
clinic or received intravenous
chemotherapy in the 30 days before
Ha et al.,
2011 [45]
Retrospective, single center study, in
319 patients with urinary infection;
Korea, 1 year
1. Hospitalization for 2 or more days in an
acute care hospital in the preceding 90 days
CAI HCAI Low
2. Resident of a nursing home or
long-term care facility
1 (1) 28 (14)
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(Continued)
3. Received intravenous therapy, wound
care or specialized nursing care at home
in the previous 30 days
4. Attended a hospital or hemodialysis
clinic or received intravenous
chemotherapy in the 30 days before
5. Received an invasive procedure,
urological surgery or urethral
catheterization in the previous 7 days
Sy et al.,
2012 [46]
Retrospective, multicenter study,
in 1,536 patients with endocarditis;
patients transferred from another
hospital, recurrent admissions or
day-stay admissions were excluded,
Australia, 6 years
1. Hospitalization for 2 days or more in the
preceding 90 days
HCAI Non-HCAI High
2. Resident of a nursing home or in a
long-term facility
40 (26) 61 (18)
3. Attended a hemodialysis clinic or
received intravenous therapy in the
30 days before
*MDR =MRSA, Pseudomonas sp, Acinectobacter, Stenotrophomonas maltophilia, ESBL. CAI, community-acquired infection; ECOG, electrocochleography; HAI,
hospital-acquired infection; HCAI, healthcare-associated infection; MDR, multidrug-resistant.
Table 3 List of all different criteria used to compose different classifications of HCAI
Criteria for HCAI Low risk of bias Moderate risk of bias High risk of bias All studies
Criteria included in the initial definition [3] Number of studies (number of patients)
Received intravenous therapy 16 (13,082) 7 (3,239) 8 (6,284) 31 (22,605)
Received wound care or specialized nursing care 16 (10,086) 5 (1,594) 7 (3,560) 28 (15,240)
Attended a hospital or a clinic in the last 30 days 16 (17,588) 5 (1,594) 5 (2,015) 26 (21,197)
Received chemotherapy in the last 30 days 15 (10,883) 6 (2,506) 7 (3,043) 28 (16,432)
Receiving hemodialysis 23 (31,272) 7 (2,639) 10 (10,470) 40 (44,381)
Prior hospitalization (in the last year) 24 (32,165) 7 (3,239) 12 (13,904) 43 (49,308)
Resident in a nursing home or long term-care facility 23 (25,468) 7 (3,239) 11 (9,361) 41 (38,068)
Criteria NOT included in the initial definition [3]
Transfer from another care facility 1 (6,697) 1 (4,543) 2 (11,240)
Immunosuppression 4 (8,669) 4 (8,669)
Active or metastatic cancer 1 (7,712) 1 (7,712)
Submitted to invasive procedures previously 1 (319) 1 (912) 1 (831) 3 (2,062)
Family member with a multi-drug resistant microorganism 2 (713) 2 (1,545) 4 (2,258)
Elderly person or physical disable persons who need healthcare 1 (893) 1 (1,385) 2 (2,278)
Surgery in the last 180 days 2 (1,056) 2 (1,056)
Received radiation therapy 1 (1,646) 1 (1,646)
Recent (30 days) treatment with antibiotics 1 (190) 1 (733) 1 (197) 3 (1,120)
HCAI, healthcare-associated infection.
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to define HCAI in patients with an infection present at
hospital admission or within 48 hours of admission are
the ones that we believe to be most important:
– received invasive procedures in the 30 days before
the infection, including specialized nursing care;
– attended a hospital or hemodialysis clinic in the
previous 30 days;
– were hospitalized in an acute care hospital for 2 or
more days in the previous year;
– resided in a nursing home or long-term care facility;
– treatment with broad spectrum antibiotics in the
last 30 days.
The initial HCAI definition [3] included treatments deliv-
ered at home or in an outpatient clinic and these criteria
have been widely adopted in other studies. The receipt
of intravenous therapy [7,14,30,31,35-39,41,45-47], wound
care or specialized nursing care [34-37,41,42,45], and
hemodialysis [7,11-14,31-42,44-46], as well as attendance
at a hospital or clinic [32,42,44,45] are important factors
as this group of patients has documented higher rates of
colonization and infection with MDR microorganisms
[48-50]. Three additional studies have included the criteria
of other previous invasive procedures [7,30,45], like uro-
logical procedures [45]. There is no reason to believe that
this last group of patients is different from the previous
ones in regards to the risks of infection by MDR organ-
isms, so we propose that the first criterion be generalized
to include all patients that received invasive procedures in
the 30 days before the infection.
The second criterion in the initial definition [3] includes
receiving chemotherapy in the last 30 days. This is a
criterion frequently used among alternative definitions
[7,14,30,31,35,38-40,42,44,45] along with having active or
metastatic cancer [11,32] that suggest receipt of some kind
of anti-cancer therapy. These are a special group of pa-
tients due to underlying immunosuppression. Immuno-
suppression, including HIV infection and treatment with
immunosuppressive agents is a criterion considered by
some authors [11,12,33,34,38,39], but specifically excluded
by others [40,44]. The variety of potential opportunistic
pathogens that may occur among this group of patients
varies largely according to the underlying cause of
immunosuppression, for example empiric antimicrobial
recommendations for a patient with advanced HIV in-
fection [51] are distinct from therapies used in patients
with acute febrile neutropenia [52]. The inclusion of
these groups of patients in a HCAI definition is possibly
one of the most controversial issues and for the moment
we suggest that they be excluded from the definition,
supported by the existence of specific recommendations
for these special populations.Nevertheless, many immunosuppressed patients, includ-
ing cancer patients would fulfill other criteria for HCAI,
such as invasive procedures, recently attending a hospital
clinic, recent hospitalization and/or recent treatment with
broad spectrum antibiotics.
Regarding previous hospitalization, we believe that this
criterion must be retained in any definition of HCAI.
The presence of MDR organisms (gram positives or gram
negatives) has been documented between six months to
one year after hospital discharge [53-55]. This risk of long
lasting colonization of both the respiratory tract and gastro-
intestinal tract with pathogens not present in the commu-
nity following hospitalization has led some authors to alter
this criterion to hospitalization in the previous six months
[12,42,44] or even one year [33]. However, the classification
of infections that develop among patients recently dis-
charged from the hospital (in the previous 14 days) is
somewhat contentious. Some authors consider these
infections occurring within 14 days of hospital discharge
nosocomial infections [48,50,56], while others consider
infections among those hospitalized in the last month as
HCAIs [11,14]. Based on the existing evidence, we propose
that in the third criterion time from the last hospitalization
will be enlarged to one year and patients discharged from
the hospital within the last two weeks be considered as hav-
ing a hospital-acquired infection.
Patients admitted from nursing homes with infection
have been extensively studied and may constitute more
than 50% of cases of healthcare-associated pneumonia
[49]. This criterion has been considered by almost all
studies; however, caution is needed with this approach.
Patients with non-severe nursing home-acquired pneumo-
nia (NHAP) have a pathogen distribution similar to those
expected in CAP [57]. Among patients with severe NHAP,
with organ dysfunction, resistant pathogens have been seen
[10,36,57]. Poor functional status and increased age have
been linked to an increased risk of infection with a MDR
pathogen among NHAP patients [20,58], and are linked
to the level of care provided in these facilities. Nursing
homes with hospital-like wards carry the same infection
risk by resistant pathogens as hospitals, and should best
be considered as the analogous to HAIs. Clinicians should
consider factors such as functional status and level of care
required in selecting treatments for patients who reside in
nursing homes.
Recent treatment with broad spectrum antibiotics has
been identified as a risk factor for infection or colonization
by MDR pathogens [59] and should also be considered
both in the definition of HCAI and in selection of em-
piric antibiotics.
Patients with close contact with a family member with
a MDR microorganism are part of the American Thoracic
Society (ATS) definition of HCAP [2]. Currently, there are
no epidemiological studies assessing the microbiological
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its inclusion on the HCAI definition.
Additional criteria not included in the initial definition
[3] represent different descriptions of the same criteria:
active or metastatic cancer, submission to invasive proce-
dures or transfer from another care facility.
There has only been one previous review on HCAI to
our knowledge. It concerns healthcare-associated pneu-
monia and is focused mainly on epidemiology [60]. The
authors performed the search in PubMed, and included
eight studies regardless of the definition used. No assess-
ment of bias was made. A description of the definitions
of HCAP used was not made. Five of those studies fo-
cused only on nursing-home acquired pneumonia.
The remaining three studies of HCAP included by the
authors were also included in the current analysis.
Recently, new definitions of Lab-ID infections were pub-
lished [61] based on laboratory testing data without a
clinical evaluation of the patient, allowing colonization
to be counted as infection. Nevertheless, this methodology
might facilitate surveillance of multi-drug resistant or-
ganisms (MDROs) among patients in the outpatient
clinic and long-term care facilities and nursing home
settings. Of notice is the fact that the document cate-
gorizes MDRO LabID events in: community-onset if
the specimen was collected as an outpatient or in-
patient three or more days after admission and health-
care facility-onset if the LabID event specimen was
collected more than three days after admission to the
facility. Following this definition, a patient with HCAI
is included in community-onset LabID event, repre-
senting from our point of view a major step backward
in the classification of infection according to place of
acquisition.
This systematic review provides the clinician with a
thorough description of all criteria available in order
to include an infected patient in the category of
HCAI, in the hope that it leads to an optimal selec-
tion of empiric antibiotic therapy in this group of pa-
tients and consequently an improvement in outcome.
It is expected that a consensus definition of HCAI
can be developed to be used in future research in
order to develop specific antibiotic recommendations
for this group of patients.
The future definition of HCAI should be universal
regardless of the focus of infection if its use is
intended to be immediate at the bedside like it hap-
pened with the classic dichotomy classification of in-
fection in community and hospital-acquired infection,
which allowed the prompt institution of adequate anti-
biotic therapy, a major prognostic factor. Nevertheless,
specific risk factors for infection by a particular micro-
organism should always be taken into account by the
clinician.Strengths and limitations
Despite the extensive research done, including electronic
search in several databases, relevant conference pro-
ceedings and a hand search of additional sources, there
is always the possibility of missing studies that could
meet the inclusion criteria.
Researcher bias is always a possibility in this type of
analysis; in order to reduce it we had two independent
researchers review the articles and a third one resolve
disagreements along with strict and simple inclusion
criteria established prior to the research.
The permissive criteria for inclusion in this study were
essential to achieve the main goal: gathering all definitions
of HCAI used in clinical studies.
We found a high rate of studies with low risk of bias,
probably related to the simplicity of the evaluation.
Considering that we only found observational studies
we think that the criteria adopted were the most adequate
to evaluate risk of bias in this type of studies.Conclusions and recommendations
The initial definition of HCAI [3] seems to be widely
accepted. Some of the included criteria, such as attend-
ance at a hospital or hemodialysis clinic in the previous
30 days and residence in a nursing home or long-term
care facility should be maintained; the precise time from
the last hospitalization is still controversial and probably
should be extended to one year. Additional criteria as
recent invasive procedures and receipt of broad-spectrum
antibiotics should be considered for inclusion in a future
definition of HCAI.
The inclusion/exclusion of immunosuppressed patients
in the definition of HCAI requires ongoing discussion.
It is expected that a consensus definition of HCAI can
be developed soon to be used in future research in order to
develop specific antibiotic recommendations for this group
of patients, with an influence from local antibiograms.Additional files
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